Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

86%

6 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(100.0%)
6Total
Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02380118Phase 4Terminated

IM Olanzapine Versus Haloperidol or Midazolam

Role: collaborator

NCT00978159Phase 4Unknown

Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia

Role: lead

NCT00852150Completed

Is a Reporting System for Gastritis or Duodenitis (Modified Lanza Scale) Reproducible?

Role: lead

NCT00683111Phase 4Completed

Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease

Role: lead

NCT01203696Phase 4Completed

Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease

Role: lead

NCT01062516Phase 4Completed

Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin

Role: lead

NCT00843063Phase 4Completed

Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion

Role: lead

All 7 trials loaded